The company says the new test overcomes a major shortcoming in faecal egg counts: that they can only detect the presence of egg-laying adult worms. The new test, by contrast, can detect all stages of the small redworm life cycle, including the important encysted larval phase.
ADB says the new test will help protect the effectiveness of moxidectin, the only dewormer which is capable of eliminating the encysted stages and against which widespread resistance is not thought to have developed.
Whereas before, routine winter treatment was needed to target the encysted phase, this new test means the drug can be kept for when it is really needed, which will help prevent the development of resistance. ADB says it will also be of great value to equine vets in making differential diagnoses.
The blood test was developed by Prof Jacqui Matthews’ group at the Moredun Research Institute (MRI), with funding from The Horse Trust. She said: "It is great to see the commercialisation of this much-needed test to support sustainable worm control in horses. The test fills an important gap in our diagnostic toolbox and will enable horse owners to work with their veterinarians in targeting anthelmintic treatments against cyathostomin infections and hence help protect these important medicines for the future."
Dr Corrine Austin from ADB said: "ADB is now developing laboratory ELISA kits to enable independent veterinary laboratories to conduct blood testing; these kits are expected to reach market during 2020. Research into the saliva-based test is ongoing and is expected to be commercialised several years from now."
Veterinary practices can contact ADB at info@austindavis.co.uk to register interest in the diagnostic test service.
Saliva was collected from 237 horses at the UK welfare charity, Bransby Horses, where EquiSal Tapeworm saliva testing was used to inform on anthelmintic administration over the course of a year. This diagnostic-led approach reduced the use of anti-tapeworm treatments by 86% compared to 6 monthly interval treatment strategies.
Austin Davis Biologics Ltd, the maker of the EquiSal Tapeworm saliva test, says it accurately diagnoses horses with a tapeworm infection, providing a low, borderline or moderate/high diagnosis.
Treatment is recommended for horses with a borderline or moderate/high result2.
In this latest study, the company says most horses diagnosed below the treatment threshold in the first saliva test remained below the threshold in the following two tests and 168 horses (71%) required no anti-tapeworm treatment at all.
Importantly, no increase in tapeworm infection prevalence was observed during the study period and only seven horses received treatment following all three saliva tests, suggesting that some horses are more susceptible to tapeworm infections.
The EVJ has prepared a podcast summarising the study findings here: https://evj.podbean.com/e/evj-of-the-hoof-podcast-no-1-march-2018-use-of-saliva-based-diagnostic-test-to-identify-tapeworm-infection-in-horses-in-the-uk/.
The study authors have also prepared a video abstract which can be viewed at https://vimeo.com/254338616 .
EquiSal saliva collection kits are available at trade prices to veterinary practices and SQPs. Contact enquiries@equisal.com or visit www.equisal.com for more information.
References